Table 2 Numbers, age, and measured plasma biomarker levels of enrolled subjects.

From: Evidence of plasma biomarkers indicating high risk of dementia in cognitively normal subjects

Group

N (female)

Age (years)

Aβ1–42 (pg/mL)

T-Tau (pg/mL)

Aβ1–42xT-Tau

MMSE

CDR

HC

37 (23)

63.1 ± 12.4

14.26 ± 1.42

15.13 ± 3.62

216.78 ± 60.89

 > 26

0

PS

27 (11)

70.7 ± 6.9**

15.43 ± 1.76*

19.29 ± 8.01*

304.06 ± 150.66*

ADFH

35 (25)

59.75 ± 4.7

15.52 ± 1.60**

17.93 ± 6.26**

285.88 ± 133.32*

Diabetes

21 (8)

75.8 ± 7.3***

16.15 ± 1.05**

19.74 ± 2.92**

320.52 ± 61.18**

ESRD

41 (16)

62.5 ± 7.8

16.52 ± 0.59**

21.54 ± 2.72**

356.59 ± 52.82**

OSA

20 (20)

40.3 ± 8.7***

15.97 ± 0.54**

20.17 ± 2.77**

322.31 ± 47.15**

AD

65 (35)

78.8 ± 8.8***

20.06 ± 3.09**

41.24 ± 14.64**

824.34 ± 302.2**

18.7 ± 4.1

1.11 ± 0.63

  1. HC healthy control, PS poststroke, ADFH family history of Alzheimer’s disease, ESRD end-stage renal disease, OSA obstructive sleep apnea, AD Alzheimer’s disease, Aβ amyloid β, T-Tau total tau protein.
  2. *p < 0.05 with respect to HC; **p < 0.01 with respect to HC; ***p < 0.001 with respect to HC.
Back to article page